F. Chai

发表

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.

J. Sosman, I. Puzanov, A. Santoro, 2012 .

Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

D. Collins, N. Tunariu, M. Germuska, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.

J. Sosman, I. Puzanov, A. Adjei, 2010 .

Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors.

N. Senzer, T. Mekhail, L. Rosen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Experience of Tivantinib in Patients with Hepatocellular Carcinoma (HCC) or Biliary Tract Cancer (BTC)

B. Schwartz, G. Abbadessa, H. Zahir, 2012 .

Regional Hyperthermia Combined with Chemotherapy in Advanced Gastric Cancer

Shenglin Ma, Lucheng Zhu, Ying Wang, 2019, Open medicine.

The Hedgehog inhibitor cyclopamine antagonizes chemoresistance of breast cancer cells

Jiangang Zhou, Jun Shi, F. Chai, 2013, OncoTargets and therapy.

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors

G. Demetri, N. Senzer, I. Judson, 2012, Cancer.

TREM-1 inhibition attenuates inflammation and tumor within the colon.

Guang-xiu Lu, Jiangang Zhou, Jun Shi, 2013, International immunopharmacology.

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

N. Senzer, T. Mekhail, L. Rosen, 2011, Clinical Cancer Research.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

L. Rosen, J. Goldman, R. Savage, 2012, Cancer.

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

J. Byrd, I. Flinn, B. Schwartz, 2019, Blood.

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

A. Tolcher, K. Papadopoulos, B. Schwartz, 2015 .

Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors.

G. Demetri, A. Pappo, L. Rosen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

J. Sosman, I. Puzanov, A. Santoro, 2014, Investigational New Drugs.

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.

J. Sosman, I. Puzanov, W. Ma, 2012 .

Abstract CT035: A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients withPIK3CAorAKT1-mutant ER+ endometrial or ovarian cancer

C. Aghajanian, B. Schwartz, K. Cadoo, 2018, Clinical Trials.

Exposure-Response Relationship to Assess the Risk of Neutropenia in Patients With Hepatocellular Carcinoma (HCC) Treated With Tivantinib

Raymond Miller, G. Abbadessa, H. Kastrissios, 2012 .

Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.

J. Sosman, I. Puzanov, A. Adjei, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.